Inclusion Criteria:

- Patients with a peritoneal carcinosis (PC) either of digestive origin or primary: a
colorectal or gastric carcinosis, a peritoneal pseudomyxoma or mesothelioma, or a
primary carcinosis of the peritoneum regardless the number of prior treatment lines.

- A PC and primary tumor considered to be resectable according to preoperative clinical
and paraclinical data: absence of mesenteric retraction and absence of bladder
invasion.

- Patients in good general health (ASA ≤ 2).

- Absence of cardiorespiratory failure (PaO2 > 60 mmHg in a stable condition, dyspnea
≤ NYHA stage 1, left ventricular ejection fraction > 60%.).

- Prothrombin level >70 %, total bilirubin < 2 x the normal level, ASAT and ALAT < 2.5
x normal levels, and alkaline phosphatases < 5 x normal levels.

- Creatinine clearance > 60 ml/min, polynuclear neutrophils > 1500/mm3, and a white
blood cell count > 4000 /mm3.

- Patients who give written, informed consent.

- Patients affiliated with the French universal healthcare system.

Exclusion Criteria:

- Patients with a PC with ovarian, mammary, biliary, pancreatic, or bronchial origin.

- Evolutive patients after systemic chemotherapy.

- Patients with a PC considered to be irresectable according to preoperative clinical
and paraclinical data: mesenteric retraction or bladder invasion.

- Patients in poor general health (ASA > 2).

- Cardiorespiratory failure (dyspnea > NYHA stage 1, PaO2 < 60 mmHg in a stable
condition)

- Prothrombin level < 70 %.

- Any brain abnormality showing on the head scan.

- Signs of heart failure and especially left ventricular ejection fraction < 60% on the
cardiac ultrasound.

- Thrombocytopenia < 100 000 / mm3

- Visceral metastases other than a single resectable liver metastasis.

- Pregnancy or breast feeding.

- Chronic inflammatory intestinal disease and/or an intestinal obstruction.

- History of severe hypersensitivity to irinotecan hydrochloride trihydrate or one of
the excipients of Campto.

- Bilirubinemia > 3 times the normal upper limit

- Yellow fever vaccine.

- Prophylactic treatment with phenytoin.

- Severe medullary insufficiency.